NASDAQ:GH Guardant Health Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Guardant Health Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $106.09 -1.58 (-1.47 %) (As of 09/23/2020 03:45 PM ET) Add Compare Share Today's Range$105.80Now: $106.09▼$109.4150-Day Range$81.62MA: $92.61▼$106.6752-Week Range$55.90Now: $106.09▼$109.50Volume12,896 shsAverage Volume1.04 million shsMarket Capitalization$10.55 billionP/E RatioN/ADividend YieldN/ABeta0.6 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingGuardant Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $113.00, Guardant Health has a forecasted upside of 3.8% from its current price of $108.85.Amount of Analyst CoverageGuardant Health has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesGuardant Health has received 184 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGuardant Health has received 153 “underperform” votes. (Add your “underperform” vote.)Community SentimentGuardant Health has received 54.60% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Guardant Health and other stocks. Vote “Outperform” if you believe GH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGuardant Health does not currently pay a dividend.Dividend GrowthGuardant Health does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Guardant Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $51,070,465.00 in company stock.Percentage Held by InsidersOnly 9.90% of the stock of Guardant Health is held by insiders.Percentage Held by Institutions84.23% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Guardant Health are expected to grow in the coming year, from ($1.49) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Guardant Health is -85.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guardant Health is -85.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGuardant Health has a P/B Ratio of 12.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.17 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GH Previous Symbol CUSIPN/A CIKN/A Webwww.guardanthealth.com Phone855-698-8887Debt Debt-to-Equity RatioN/A Current Ratio14.42 Quick Ratio14.13Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$214.38 million Price / Sales49.20 Cash FlowN/A Price / Cash FlowN/A Book Value$8.50 per share Price / Book12.48Profitability EPS (Most Recent Fiscal Year)($0.84) Net Income$-75,650,000.00 Net Margins-45.53% Return on Equity-13.35% Return on Assets-11.34%Miscellaneous Employees454 Outstanding Shares99,424,000Market Cap$10.55 billion Next Earnings Date11/5/2020 (Estimated) OptionableNot Optionable $106.09 -1.58 (-1.47 %) (As of 09/23/2020 03:45 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GH News and Ratings via Email Sign-up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter. Guardant Health (NASDAQ:GH) Frequently Asked Questions How has Guardant Health's stock price been impacted by COVID-19 (Coronavirus)? Guardant Health's stock was trading at $62.95 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GH shares have increased by 68.5% and is now trading at $106.09. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Guardant Health? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Guardant Health. When is Guardant Health's next earnings date? Guardant Health is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Guardant Health. How were Guardant Health's earnings last quarter? Guardant Health Inc (NASDAQ:GH) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.17. The business had revenue of $66.30 million for the quarter, compared to the consensus estimate of $59.18 million. Guardant Health had a negative net margin of 45.53% and a negative return on equity of 13.35%. The company's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.13) earnings per share. View Guardant Health's earnings history. What price target have analysts set for GH? 7 equities research analysts have issued twelve-month price objectives for Guardant Health's shares. Their forecasts range from $100.00 to $130.00. On average, they anticipate Guardant Health's stock price to reach $113.00 in the next year. This suggests a possible upside of 6.5% from the stock's current price. View analysts' price targets for Guardant Health. Who are some of Guardant Health's key competitors? Some companies that are related to Guardant Health include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), InVitae (NVTA), Natera (NTRA), ELEKTA AB/ADR (EKTAY), Burning Rock Biotech (BNR), CareDx (CDNA), Veracyte (VCYT), Castle Biosciences (CSTL), Genetron (GTH), Fulgent Genetics (FLGT), Personalis (PSNL), RadNet (RDNT), ALX Oncology (RNLX) and Progenity (PROG). View all competitors. What other stocks do shareholders of Guardant Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), Okta (OKTA), Alteryx (AYX), Paypal (PYPL), Shopify (SHOP), Twilio (TWLO) and Roku (ROKU). Who are Guardant Health's key executives? Guardant Health's management team includes the following people: Mr. AmirAli Talasaz, Chairman, Pres & COO (Age 40)Dr. Helmy Eltoukhy Ph.D., Co-Founder, CEO & Director (Age 40)Mr. Michael J. Wiley, Chief Legal Officer (Age 44)Mr. Derek A. Bertocci, Chief Financial Officer (Age 65)Dr. Richard B. Lanman, Chief Medical Officer (Age 64) When did Guardant Health IPO? (GH) raised $200 million in an IPO on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers. What is Guardant Health's stock symbol? Guardant Health trades on the NASDAQ under the ticker symbol "GH." Who are Guardant Health's major shareholders? Guardant Health's stock is owned by many different retail and institutional investors. Top institutional investors include SB Investment Advisers UK Ltd. (14.12%), Vanguard Group Inc. (6.36%), Jennison Associates LLC (3.53%), Viking Global Investors LP (3.24%), Nuveen Asset Management LLC (3.02%) and Coatue Management LLC (1.58%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank. View institutional ownership trends for Guardant Health. Which institutional investors are selling Guardant Health stock? GH stock was sold by a variety of institutional investors in the last quarter, including SB Investment Advisers UK Ltd., Viking Global Investors LP, Coatue Management LLC, Sumitomo Mitsui Trust Holdings Inc., AlpInvest Partners B.V., Advisor Group Holdings Inc., Nicholas Investment Partners LP, and Wisconsin Capital Management LLC. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, and Timothy P Eckersley. View insider buying and selling activity for Guardant Health. Which institutional investors are buying Guardant Health stock? GH stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Nuveen Asset Management LLC, Marshall Wace LLP, Jennison Associates LLC, Bamco Inc. NY, Marshall Wace North America L.P., SeaTown Holdings Pte. Ltd., and Summit Partners Public Asset Management LLC. View insider buying and selling activity for Guardant Health. How do I buy shares of Guardant Health? Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Guardant Health's stock price today? One share of GH stock can currently be purchased for approximately $106.09. How big of a company is Guardant Health? Guardant Health has a market capitalization of $10.55 billion and generates $214.38 million in revenue each year. The company earns $-75,650,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Guardant Health employs 454 workers across the globe. What is Guardant Health's official website? The official website for Guardant Health is www.guardanthealth.com. How can I contact Guardant Health? Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887. This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
